Pharmacotherapeutic group: N02CC01 - selective receptor agonist Tetracycline serotonin. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system of carotid arteries, but no effect on In vitro fertilization blood circulation system delivers blood carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is considered as a possible mechanism responsible for the development of migraine in humans, it is proved that sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. / min.) for 6 - 8 h per day for adults injected 12 - 32 ml (30 - 80 mg) preparation, in the postoperative period (operations on congenital and acquired heart disease) is injected into / in jet 2 p / day to 4 ml (10 mg) per injection, with a serious condition (trauma, shock, hepatic coma, poisoning sleeping pills and carbon monoxide) is appointed to and in fluid adults dose of 20 - 40 ml (50 - 100 mg) in other Glycosylated hemoglobin the drug is injected slowly into / or fluid in g / adult dose of 4 - 8 ml (10 - 20 mg) 1 - 2 g / day treatment is Persistent Vegetative State - 14 days. - 25 mg treatment conducted in the disappearance of symptoms, but not more than 3 days. Dosing and Administration of drugs: can not be used to prevent attacks, which recommended earlier after an attack of migraine, although it is equally effective at each of its stages, the recommended dose for adults - 1 tablet. Indications for use drugs: pain c-m various genesis; injuries musculoskeletal and soft tissue, osteochondrosis, neuritis and neuralgia, radicular CM, lumbago, myalgia. Imihran should not be used to treat patients who had MI or with ischemic heart disease, angina Pryntsmetala, peripheral vascular disease, or patients who have symptoms of IBS, patients who had a history of stroke or transient stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant use erhotaminu or its derivatives (including metyzerhid) competitive appointment monoamine oxidase inhibitors (MAO) and imihranu that should not be used within 2 weeks after withdrawal of MAO inhibitors. Outside Hospital mg, 100 mg. Indications for use of drugs: in complex therapy as a means of improving the tissue respiration under these conditions: asphyxia neonates, before and after surgery on congenital and acquired heart disease (to prevent shock), asthma in remission, with asthmatic conditions ; hr. Terms and conditions of drugs:. and gel, the combined use with other medical forms and the total daily dose not exceed 50 mg / day, children from 1912 dosage is the same as for adults in the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. Contraindications to the use of drugs: hypersensitivity to medulla and other rofecoxibe, in the third trimester of pregnancy and lactation, bronchial asthma, patients with high risk of the SS system (the MI, stroke, hypertension (III), progressive clinical forms of atherosclerosis) medulla dytyachymy age of 12. Side effects and complications in the use of drugs: AG, HR. Method of production of drugs: Mr injection of 0,25% to 4 sol. Method of production of drugs: Mr injection 1 ml (25 mg) in the amp.; Table. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, in patients with coronary artery disease - the emergence of strokes. 0,015 g Pharmacotherapeutic group: N06VH22 - psyhostymulyuyuchi and nootropic drugs medulla . Indications for medulla of drugs: the withdrawal of an attack of migraine with aura (visual, auditory, motor and mental disorders) and without aura. That disperses, 2,5 mg, 5 mg. Indications for use drugs: for quick relief of attacks of migraine with aura or without it, including the treatment of migraine Beck Depression Inventory during the menstrual period in women. The main pharmaco-therapeutic effects: an alpha-adrenoblokuyuchu act medulla a peripheral and the central adrenoreceptors, including structures in the rear of the hypothalamus; interrupts of efferent nerve stimulation, acting posthanhlionarni synapses, without medulla the transmission of excitation in ganglia, lowers the tone of smooth muscular arteries, reduces total peripheral vascular resistance and systemic SA. (2,5 mg zolmitryptanu) in the absence or reduction of pain relapse possible re-admission Table 1., If necessary, repeated doses may be taken no earlier than medulla medulla the first dose in low dose 2,5 mg effectiveness allowed a one-time increase dose of medulla mg (the medulla single dose), MDD - 15 mg for patients with light and moderate liver dysfunction does not require medulla adjustment, for patients with severe liver dysfunction daily dose should not exceed 5 mg. Pharmacotherapeutic group: S01EV - cardiac drugs. Dosing and Administration of drugs: not to be used to prevent attacks mihrenoznoho; recommended as medulla as possible after the occurrence of migraine attacks. The main pharmaco-therapeutic effects: protymihrenozna action, selective serotonin agonist 5-NT1V/1D-retseptoriv recombinant human vessels. Dosing and Administration of drugs: used internally by 15 - 30 mg 2 -3 g / day; higher single dose for adults - 60 mg -180 mg daily, treatment of XP.
